Primary Ovarian insufficiency (POI) affects 1% of women under forty. We studied a patient 26 with a non-syndromic POI, from a consanguineous Turkish family. Exome sequencing 27 identified a homozygous missense variant c.8524C>T/p.R2842C in BRCA2. BRCA2 is a major 28 player in homologous recombination (HR). BRCA2 deficiency induces cancer predisposition 29 and Fanconi Anemia (FA). Remarkably, neither the patient nor her family exhibit somatic 30 pathologies. The patient's somatic cells presented intermediate levels of chromosomal breaks, 31 cell proliferation and radiation-induced RAD51 foci formation when compared to controls, the 32 heterozygous mother's and FA cells. R2842C-BRCA2 partially complemented BRCA2 33 depletion for double-strand break-induced HR. The residual HR function in patient's cells could 34 explain the absence of somatic pathology. BRCA2 is expressed in human fetal ovaries in 35 pachytene stage oocytes, when meiotic HR occurs. This study has a major impact on the 36 understanding of genome maintenance in somatic and meiotic cells and on the management of 37 POI patients. 38 39 Keywords: BRCA2 / mutation / cancer / Fanconi anemia / Primary ovarian insufficiency / 40 meiosis. 41 42
INTRODUCTION 43
Primary ovarian insufficiency (POI) is a public health issue affecting ~1% of women under 40 44 years, and is clinically heterogeneous with isolated or syndromic forms (Huhtaniemi et al., 45 2018 developmental anomalies and cancer predisposition (Hoeijmakers, 2009 ).Homologous 52 recombination (HR), an evolutionary conserved process essential to genome stability and cell 53 viability, plays crucial roles in DNA double strand break (DSB) repair in somatic and meiotic 54
cells. 55
In mammals, BRCA2 binds damaged DNA and loads the pivotal HR player RAD51, which then 56 promotes DNA homology search. Therefore, cells defective in RAD51 or BRCA2 are thus 57 defective in mitotic HR (Lambert and Lopez, 2000 ; Moynahan et al., 2001) . Heterozygous 58 BRCA2 mutations increase susceptibility to breast and ovarian cancers, whereas severe bi-allelic 59 defects in RAD51 (FANCR) or BRCA2 (FANCD1) lead to Fanconi anemia (FA) syndrome (Tsui 60 and Crismani, 2019). In particular, FANCD1 syndrome associates developmental defects, 61 genetic instability, bone marrow failure and cancer predisposition, with cancer developing in 62 the first decade of life, and death before puberty (Meyer et al., 2014) . The role of BRCA2 in 63 RAD51 loading in mitotic HR makes it a strong candidate for an involvement in meiotic HR, 64 but this remains to be formally established. Indeed, the severe phenotypes of bi-allelic 65 inactivation of BRCA2 in humans and the early embryonic lethality resulting from germ-line 66 inactivation of this essential gene in animal models hampered meiosis analysis and 67 compromised the study of the putative functions of BRCA2 in gametogenesis (Ludwig et al., 68 1997 ; Sharan et al., 1997; Tsuzuki et al., 1996) . 69 We describe here an adult patient carrying a homozygous missense mutation in BRCA2 with 70 isolated POI, but without cancer nor FA traits in the patient or her family. We demonstrate that 71 the mutated R2842C-BRCA2 retains a lower but significant residual function when compared 72 to wild-type (WT)-BRCA2. Consistently, the patient's cells exhibit intermediate levels in 73 chromosomal breaks, cell proliferation and ionizing radiation-induced RAD51 foci formation 74 when compared to controls, a FANCD1 patient's or the heterozygous mother's cells. This 75 residual HR in somatic cells could explain the absence of in vivo somatic pathologies. BRCA2 76 is a major cancer susceptibility gene and our finding will have a strong impact on the genetic 77 counselling and management of patients with POI and their relatives. 78 79 RESULTS 80
Case report 81
The proposita was born to consanguineous Turkish parents (Figure 1 ). At 13 years, she had two 82 vaginal bleedings followed by primo-secondary amenorrhea. She had normal pilosity, breast 83 development and external genitalia. Several hormonal assays confirmed POI and pelvic 84 ultrasonographical studies showed small ovaries with no or very few follicles (Table 1 ). Blood 85 counts, liver and thyroid balances were normal. Thyroid auto-antibodies were undetectable. 86
Bone densitometry at 30 years showed a marked osteopenia (T score = -2.3). She is presently 87 41 years old, displays normal blood assays and no other clinical sign. The karyotype is 46, XX 88 and FMR1 premutation screening was negative. After two egg-donation procedures, she had 89 two pregnancies with four healthy children. The patient and family members have a normal stature, normal head circumferences with no 98 abnormality in skin pigmentation, skeletal development or dysmorphia (Table 1 ). There was no 99 familial history of infertility or other diseases. The mother married at the age of 15 and had two 100 pregnancies at 18 (a boy) and 22 years (the proposita). This is in line with a delayed conception 101 followed by secondary amenorrhea at the age of 33, not investigated in Turkey. She is obese 102 with a BMI of 38. In order to rule out other genetic causes that could explain her subfertility, 103 we performed a targeted NGS (see supplementary information). The brother had one healthy 104 son (17 years) and 3 healthy daughters aged 15, 13 (both with normal puberty) and 8 years. The 105 71 years-old father, a heavy smoker, had a lung cancer at the age of 67 years, treated by 106 radiotherapy and chemotherapy. A paternal uncle developed a colorectal cancer at the age of 74 107 years and died few months later. Six other paternal and maternal uncles and aunts are 61 to 75 108 years old and have no history of cancer or infertility. Immunostaining of human fetal ovarian sections showed that BRCA2 protein was detected 172 mostly in pachytene stage oocytes ( Figure 3B ). BRCA2 staining appeared as thick threads, 173 likely corresponding to meiotic chromosomes. These results show that BRCA2 is indeed present 174 on chromosomes in fetal human oocytes when meiotic DSB repair occurs. 
R2842C-BRCA2 displays a reduced DSB-induced HR efficiency 187
Although referenced in the COSMIC database of variants in cancer (COSM23938), R2842C-188 BRCA2 is considered as a variant of unknown significance for breast cancer predisposition 189 (VUS, IARC class 3). Attempts to classify BRCA2 VUS in a hamster lung fibroblast cell line 190 showed that this variant displayed a little decrease in HR efficiency, at the limit for inferring 191 pathogenicity (Guidugli et al., 2013) . Therefore, the significance of this variant and its 192 classification as a causal mutation for human pathology remained unclear. A previous attempt 193 to classify BRCA2 VUS in a hamster lung fibroblast cell line showed that this variant displayed 194 a little decrease in HR efficiency, at the limit for inferring pathogenicity (Guidugli et al., 2013). 195 Since human and rodent cells differ in their regulation of DSB repair, we analysed the specific 196 impact of R2842C-BRCA2 on HR in human cells. We used the RG37 cell line (Dumay et al., 197 2006 ), a human SV40 immortalized fibroblast line bearing the DR-GFP substrate (Pierce et al., 198 1999 ) that monitors gene conversion induced by targeted cleavage by the I-SceI meganuclease 199 ( Figure 4A ). Both the expression of WT-BRCA2 and R2842C-BRCA2 stimulated the efficiency 200 of DSB-induced HR ( Figure 4B ). We then silenced the endogenous BRCA2 using a specific 201 siRNA targeting its 3'UTR sequence, and complemented these cells with either the WT or 202 mutated BRCA2 ( Figure 4C ). As expected, silencing endogenous BRCA2 decreased HR 203 efficiency, and WT-BRCA2 fully complemented HR efficiency. R2842C-BRCA2, expressed at 204 similar levels than WT-BRCA2, only partially complemented HR efficiency, to 67 ± 6% 205 compared to WT-BRCA2 ( Figure 4B ). 206
These data show that the R2842C-BRCA2 mutation affects HR efficiency in human cells, but 207 only partially. This significant residual activity could account for the absence of somatic 208 pathology in the patient. Then we compared the proliferation rate of primary fibroblasts from the POI patient, WT 244 controls and a FANCD1 patient. As expected, the proliferation of FANCD1 cells was markedly 245
affected when compared to that of the WT cells ( Figure 5C The main role for BRCA2 is the loading of the pivotal RAD51 recombinase on damaged DNA, 265 a crucial step for triggering HR. Therefore, we monitored the radiation-induced assembly of 266 RAD51 foci, which are considered sites of HR initiation events. As expected, FANCD1 cells 267 failed to assemble RAD51 foci ( Figure 6A and 6B). The patient's cells showed an intermediate 268 phenotype: indeed, at 6 Gy, they assemble foci with kinetics comparable to WT cells, but the 269 level of the plateau was about two-fold lower than in WT cells ( Figure 6B) . A dose-response 270 analysis confirmed the complete deficiency in RAD51 foci assembly in FANCD1 cells, at all 271 irradiation doses ( Figure 6C and 6D ). In the patient's cells, the number of RAD51 foci increased 272 up to 2 Gy similarly to WT cells, but did not further increased at higher doses ( Figure 6C We report here for the first time a BRCA2 homozygous hypomorphic mutation in a patient with 304 POI, and, remarkably, without cancer nor Fanconi anemia traits in the patient and her family. 305
The mutation is located in the ssDNA-binding domain of BRCA2. We performed a thorough 306 functional study and showed that the R2842C-BRCA2 mutant displays a reduced residual HR 307 activity. Consistently, the patient's cells exhibit a reduced rate of proliferation, a slight increase 308 in MMC-induced chromosomal breaks and a dose-sensitive alteration of radiation-induced 309 assembly of RAD51 foci. However, despite these moderate alterations in somatic cells, the 310 patient did not develop somatic pathology, unlike FANCD1 patients. 311
Meiotic recombination is a complex and highly regulated process occurring in meiotic 312 prophase I and involving specific meiotic genes such as DMC1 and MEIOB (Crickard et al., 313 2018; Souquet et al., 2013; Yoshida et al., 1998) . While the role and clinical impact of 314 homozygous and heterozygous BRCA2 variants in mitotic cells is widely studied, the impact of 315 such defects in human germ cells remains less understood because almost all FANCD1 patients 316 die before puberty. However, it was very recently shown in mouse models that oocyte-specific 317
Brca2 defects lead to meiotic impairment, germ cells depletion and infertility (Miao et al., 2019; 318 Tsui and Crismani, 2019). Here, we show that BRCA2 mRNA and protein are expressed in 319 human fetal ovaries in pachytene stage oocytes, when meiotic HR occurs. Taken together, our 320 data strongly support an actual role of BRCA2 in meiotic HR, and therefore a likely impact of 321 R2842C-BRCA2 reduced activity on this process in our POI patient. 322
The main role of BRCA2 is the loading of the pivotal recombinase RAD51 on damaged DNA, 323 to allow for repairing DSBs by HR. Using a HR reporter assay and quantification of RAD51 324 foci in the patient's irradiated somatic cells, we show here that the R2842C-BRCA2 mutant 325 exhibits a reduced DSB-induced HR efficiency, but that RAD51 foci assembly was not affected 326 at low irradiation doses. In addition, the patient's cells displayed a growth rate and levels of 327 chromosomal breaks intermediate between FANCD1 cells and WT cells. This shows that the 328 patient's somatic cells are slightly altered when compared to WT cells, but at a level insufficient 329 to cause somatic pathological consequences. Since R2842C-BRCA2 cells efficiently load 330 RAD51 on low numbers of DNA damage, the residual HR activity of the R2842C-BRCA2 331 mutant could account for the absence of somatic disorders. 332
Meiotic recombination in germ cells is initiated by hundreds of DSBs, and crossing-overs 333
(involving HR) are required to produce functional gametes (Zhang et al., 2019) . By contrast, 334 somatic DSBs are introduced by accident and such cells are rarely spontaneously confronted to 335 such high levels of simultaneous DSBs. In our functional test, RAD51 foci assembly by the 336 mutated BRCA2 was significantly decreased at higher doses (>5 Gy) that generate a high 337 number of DSBs (with an estimation of 30 to 40 DSB/Gy/mammalian genome (Ruiz de  338 Almodóvar et al., 1994)). Therefore, the R2842C-BRCA2 mutation is expected to affect the 339 processing of such a high number of simultaneous meiotic DSBs, explaining the infertility 340 observed in our patient. 341
Heterozygous BRCA2 mutations increase susceptibility to familial breast and ovarian cancer 342 In conclusion, we describe and functionally characterize here for the first time a homozygous 358 hypomorphic variant of BRCA2, in a patient with isolated POI without somatic pathology in 359 the patient and her family. The recent implication of DNA repair genes in POI establishes a 360 genetic link between infertility and cancer. As BRCA2 is a major susceptibility gene for breast 361 and ovarian cancer, this represents a major ethical issue for the care of these patients. It should 362 change the genetic counselling and pre-test information for patients with isolated POI and their 363 families. Indeed, such counselling should be addressed while keeping in mind a possible defect 364 in major DNA repair genes such as BRCA2. More generally, this study has also a wide impact 365 for the understanding of the processes controlling genome plasticity and the consequences of 366 their defects, in somatic and germ cells. 367
368

MATERIAL AND METHODS 369
Ethics statement 370
The study was approved by all the institutions involved and by the agence de Biomedecine 371 (reference number PFS12-002). Written informed consent was received from participants prior 372 to inclusion in the study. 
Collection of human fetal gonads 409
Human fetal ovaries were obtained and studied as described (Frydman et al., 2017) . Fetal ovaries 410 were harvested from material obtained following legally induced abortions or therapeutic 411 terminations of pregnancies at the Department of Obstetrics and Gynecology at the Antoine 412 Béclère Hospital, Clamart (France). All women provided an informed consent and this study 413 was approved by the Biomedicine Agency (reference number PFS12-002). Fetal age was 414 calculated by measuring the length of limbs and feet according to a developed mathematical 415 model (Evtouchenko et al., 1996) . After collection, fetal gonads were stored in RLT RNA lysis 416 buffer (Qiagen, Courtaboeuf, France) for gene expression profiling or fixed for histology and 417 immunostaining. Fetal ovaries from the therapeutic terminations of pregnancies (second and 418 third trimester of pregnancy) had to display normal histological features before being included 419 in the study. 420
421
Detection of BRCA2 in human fetal ovaries 422
Immunohistochemistry was studied as previously described (Poulain et al., 2015) . Fetal human 423 ovaries were fixed overnight in 10% neutral formalin (Carlo Erba Reagents, Val de Reuil, Frane) 424 before being dehydrated, embedded in paraffin wax and cut into 5µm sections. After dewaxing 425 and rehydration, antigen retrieval was performed in HIER citrate buffer pH 6 (Zytomed, 426 Diagomics, Blagnac, France) in an autoclave (Retriever 2100, Proteogenix, Mundolsheim, 427 France). Sections were then bathed in distilled water and incubated for 15 min in 3% H2O2 at 428 room temperature. After 30 min in 2.5% normal Horse serum (Vector laboratories, Eurobio, Les 429 Ulis, France), primary antibody diluted in PBS was incubated for 2h at 37°C. The primary 430 antibody used in this study was rabbit polyclonal to human BRCA2 (1:200, Abcam, Paris, 431 France). The primary antibody was revealed using the secondary antibody anti-rabbit IgG 432 (IMPRESS kit, Vector Laboratories, Eurobio). Peroxidase activity was visualized using VIP 433 (Vector laboratories, Eurobio) as a substrate. Sections were counterstained with hematoxylin. 434
Real-time quantitative PCR 436
In order to measure the expression of multiple genes during human gonadal development, total 437 RNA from fetal ovaries was extracted using the RNeasy Mini Kit (Qiagen Courtaboeuf, France), 438 followed by a reverse transcription and whole transcriptome amplification (Quantitect Whole  439 Transcriptome cDNA Amplification, Qiagen, Courtaboeuf, France). Seventeen ovaries were 440 included for gene expression profiling as previously described (Poulain et al., 2014) . Each RNA 441 sample was analysed in triplicate. The 7900HT Fast Real-Time PCR System (Applied 442 Biosystems, Foster City, CA) and SYBR-green labelling were used for quantitative RT-PCR. 443
The comparative ∆∆cycle threshold method was used to determine the relative quantities of 444 mRNA using ACTB (ß-actin) mRNA as reference gene for normalization. The sequences of 445 oligonucleotides used with SYBR-green detection were designed with Primer Express Software: and 0.05% Tween20 and probed with anti-RAD51 antibody (1/500, PC130, Merck Millipore) 510 for 2 h at 37°C. After 3 washes in PBS-Tween20 (0.05%) at RT, the cells were probed with 511
Alexa-coupled anti-mouse or anti-rabbit secondary antibody (1/1,000, Invitrogen) for 1h at 512 37°C. After 3 washes, the cells were mounted in DAKO mounting medium containing 300 nM 513 DAPI and visualized using a fluorescence microscope (Zeiss Axio Observer Z1) equipped with 514 an ORCA-ER camera (Hamamatsu). Image processing and foci counting were performed using 515 the ImageJ software. The second variant was the BRCA2 missense rs80359104 characterized in this study. 711 712 Targeted Next Generation Study in the mother 713 The patient's mother had delayed conception followed by secondary amenorrhea at the age of 714 33 years, not investigated in Turkey. Her amenorrhea, reflecting either a central or peripherical 715 hypogonadism, could be explained in part by obesity, known to contribute to ovulatory 716 dysfunction and amenorrhea (Mircea et al., 2007) . Thus, we performed a targeted next 717 generation sequencing (NGS) to eliminate other genetic cause that might explain the potential 718 precocious menopause in the mother. We obtained an average of 1 Gb of sequences with more 719 than 98% of mappable reads and a mean depth of 150x. Nearly 96% of bases were covered to 720 a minimum depth of 20x and more than 95% of the read bases had a Qscore of above 30. A 721 total of four hundred and thirty-seven (437) variants were detected. Twenty variants have a 722 frequency lower than 2% according to the ExAC base. Six false positive variants were ruled 723 out with a careful examination of the corresponding BAMs using IGV. Of the 14 remaining 724 variants, 8 are intronic variants with no predicted effect on splicing. Of the 6 exonic variants, 725 one is a synonymous variant without impact on splicing. Of the remaining five exonic variants, 726 4 are predicted to be benign by the M-CAP prediction software (Table S1 ). The only remaining 727 variant was the BRCA2 missense mutation detected in the propositus (our patient, Figure 1 , 728 V2), BRCA2: c. c.8524C>T; p. Arg2842Cys. 729 BRCA2 heterozygous mutations were associated with lower AMH levels, reflecting the ovarian 730 reserve (Daum et al., 2018) . We cannot exclude that the heterozygous R2842C-BRCA2 731 mutation could have an impact on the mother's ovarian reserve in addition to environmental 732 factors. 733 734 
